Impact of Pathologic Complete Response following Neoadjuvant Chemotherapy ± Trastuzumab in Locally Advanced Breast Cancer.
Taher Al-TweigeriMahmoud ElshenawyAhmad BadranAyman OmarKausar SulemanOsama Al MalikIhab AnwarNoha JastaniyaAsma TulbahMohammad Al ShabanahDahish AjarimAdher Al SayedPublished in: Journal of oncology (2021)
Women with ER+/HER2- disease are the least likely to achieve pCR, with the highest rates in HER2+ and triple-negative subgroups. Degree of response is associated with OS; despite the comparatively higher likelihood of achieving pCR in ER-/HER2+ and triple-negative, these subgroups experience a survival detriment. We are consistent with the published data that patients who attain the pathological complete response defined as ypT0/ypN0 have improved outcomes.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- rectal cancer
- squamous cell carcinoma
- sentinel lymph node
- lymph node
- estrogen receptor
- radiation therapy
- endoplasmic reticulum
- phase ii study
- breast cancer cells
- electronic health record
- epidermal growth factor receptor
- real time pcr
- big data
- randomized controlled trial
- adipose tissue
- tyrosine kinase
- meta analyses
- study protocol